Structure Therapeutics Q2 net loss $106.2M; Phase 3 ACCOMPLISH program dosed first patients

Structure Therapeutics Inc.

Net loss of $106.2M in Q2 2026 vs $61.7M in Q2 2025; R&D expenses $100.1M (up from $54.7M).
Cash, equivalents and short-term investments $1.3B as of June 30, 2026, expected to fund operations through 2028.
First patients dosed in Phase 3 ACCOMPLISH-1 and -2 trials of aleniglipron for chronic weight management.
Appointed John Berrios (ex-Novo Nordisk) as Chief Commercial Officer.
Phase 1 SAD data for ACCG-2671 and initiation of MAD trial on track for Q3 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.